TuberculosisPhase 1NCT02606214
A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
A Phase 1 study testing TBA-354 in people with Tuberculosis, run by Global Alliance for TB Drug Development.
Trial summary
The objective of the study is to evaluate the safety and tolerability of multiple doses of TBA-354 in healthy subjects. Read more about this study
- Who is it for?
- Ages 19 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Tuberculosis
- What is being tested?
- TBA-354
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 18 participants
- Where
- No sites listed yet
- Study dates
- Nov 2015to Dec 2016
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy adult male and females of non-childbearing potential, 19 to 50 years of age (inclusive) at the time of screening.
- Body mass index (BMI) ≥ 18.5 and ≤ 32.0 (kg/m2) and a body weight of no less than 50.0 kg.
- Medically healthy with no clinically significant screening results (e.g., laboratory profiles, medical histories, vital signs, ECGs, physical examination) as deemed by the Investigator.
- No use of tobacco or nicotine containing products (including smoking cessation products), for a minimum of 6 months prior to dosing.
- Females of non-childbearing potential, having undergone one of the following sterilization procedures at least 6 months prior to dosing:
- Hysteroscopic sterilization
Show all 17Show fewer
- Bilateral tubal ligation or bilateral salpingectomy
- Hysterectomy
- Bilateral oophorectomy
- or be postmenopausal with amenorrhea for at least 1 year prior to the first dose with serum follicle stimulating hormone (FSH) levels consistent with postmenopausal status at screening.
- Non-vasectomized males (or males vasectomized less than 120 days prior to study start), must agree to the following during study participation and for 90 days following the last administration of study drug:
- use a condom with spermicide while engaging in sexual activity or be sexually abstinent
- not donate sperm during this time.
- In the event the sexual partner is surgically sterile, use of a condom with spermicide is not necessary. None of the restrictions listed above are required for vasectomized males whose procedure was performed more than 120 days prior to study start.
- Willing to answer inclusion and exclusion criteria questionnaire at check-in.
- Subject understands study procedures and provides written informed consent for the trial.
- Be able to comply with the protocol and the assessments therein, including all restrictions.
Who cannot join
- History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease as determined by the Investigator to be clinically relevant.
- History of any illness that, in the opinion of the Investigator, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
- Surgery within the past 90 days prior to dosing as determined by the Investigator to be clinically relevant.
- History or presence of alcoholism or drug abuse within the past 2 years as determined by the Investigator to be clinically relevant.
- Hypersensitive or idiosyncratic reactions to compounds related to TBA-354 (e.g., nitroimidazoles such as metronidazole, etc.).
- Female subjects who are pregnant or lactating.
Show all 38Show fewer
- Positive results for the urine drug/alcohol screen at screening or check-in.
- Positive urine cotinine at screening.
- Serum magnesium potassium, or calcium laboratory values outside of the normal range at screening.
- Positive results at screening for Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HBsAg), or Hepatitis C antibodies (HCV).
- Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
- Heart rate is lower than 40 bpm or higher than 99 bpm at screening.
- Any electrocardiogram abnormality at Screening (as deemed by decision of the Investigator and the Sponsor's Medical Monitor).
- NOTE: The following can be considered not clinically significant without consulting the Sponsor's Medical Monitor:
- Mild first degree A-V block (P-R interval <0.23 sec)
- Right or left axis deviation
- Incomplete right bundle branch block
- Isolated left anterior fascicular block (left anterior hemiblock) in younger athletic subjects
- QTcF interval >450 msec for males or >470 msec for females at screening, Day -2, Day -1, or Day 1 (pre-dose), or history of prolonged QT syndrome.
- Family history of Long-QT Syndrome or sudden death without a preceding diagnosis of a condition that could be causative of sudden death (such as known coronary artery disease, congestive heart failure or terminal cancer).
- History of one or any combination of, the following:
- Seizures or seizure disorders
- Brain surgery.
- History of head injury in the last five years
- Any serious disorder of the CNS or related neurological system, particularly one that may lower the seizure threshold. v. History of seizures
- Use of any prescription medication within 14 days prior to dosing.
- Use of any over-the-counter (OTC) medication, including herbal products and vitamins, within the 7 days prior to dosing, except acetaminophen. Up to 3 grams per day of acetaminophen is allowed at the discretion of the Investigator prior to dosing.
- Use of any drugs or substances known to be significant inhibitors of Cytochrome P450 (CYP) enzymes and/or significant inhibitors or substrates of P-glycoprotein (P-gp) and/or Organic anion transporting polypeptides (OATP) within 14 days prior to the first dose of study drug.
- Use of any drugs or substances known to be inducers of CYP enzymes and/or P-gp, including St. John's Wort, within 28 days prior to the first dose of study drug.
- Use of any drugs or substance known to lower the seizure threshold.
- Blood donation or significant blood loss within 56 days prior to dosing.
- Plasma donation within 7 days prior to dosing.
- Participation in another clinical trial within 28 days prior to dosing.
- Prior treatment with investigational products pretomanid or OPC-67683.
- Consumption of the following prior to dosing period:
- Alcohol 48 hours prior to dosing
- Grapefruit/Oranges 10 days prior to dosing
- Caffeine/Xanthine 24 hours prior to dosing
About this study
Official title: A Phase I, Double-Blind, Placebo Controlled, Randomized, Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
The objective of the study is to evaluate the safety and tolerability of multiple doses of TBA-354 in healthy subjects.
Read the detailed description
This is a randomized, double-blind, placebo-controlled, multiple ascending dose study conducted at one study center in the United States. Three (3) multiple ascending dose cohorts are planned with twelve (12) healthy subjects (9 active and 3 placebo) in each cohort. There will also be a dose formulation comparison cohort, enrollment of six (6) subjects is planned. An additional multiple dose cohort of twelve (12) subjects may be enrolled.
Safety will be assessed throughout the study; serial ECGs and serial blood samples will be collected for the safety and pharmacokinetics (PK) assessment of TBA-354.
Dose escalation to the next cohort (i.e., dose level) will not take place until the Sponsor, in conjunction with the Principal Investigator, has determined that adequate safety, tolerability and PK from the previous cohort has been demonstrated to permit proceeding to the next cohort. Upon review of cohort data, the Sponsor, in conjunction with the Principal Investigator, may decide to:
- Escalate the dose as planned.
- Evaluate an intermediate dose level prior to proceeding to the next planned dose level if concerns arise from PK and safety that do not warrant in ceasing escalation.
- Repeat a given dose level in a new cohort of subjects.
- Increase the dose of the next cohort if the PK is lower than expected in the previous cohort.
- Add a cohort if the PK is lower than expected after a cohort and there are no safety concerns.
- Halt the study.
During dose escalation, at no time will the projected Cmax of any individual exceed 7.6 µg/mL, which is the highest mean value at the no-observed-adverse-effect-level from the 3-month log toxicology study TBA 354 NCLN-103. The predicted median Cmax of the final cohort can exceed 3.2 µg/mL only if there have been no safety concerns.
Subjects in the Multiple Ascending Dose (MAD) Cohorts will be housed in the Celerion clinic from check-in to Day 15. Subjects will return to the clinic each day from Day 16-Day 21 and have a final one-week follow up phone interview upon completion. Subjects in the Dose Formulation Cohort will be housed in the Clerion clinic from check-in to Day 3, visit the clinic each day for Days 4-7, and be housed in the clinic for Days 14-16. Then subjects will return for a daily visit for Days 17-20, and be contacted for a final one-week follow up phone interview upon completion on Day 28.
- Conditions
- Tuberculosis
- Being tested
- TBA-354, TBA-354 Placebo
- Keywords
- Tuberculosis, TBA-354, Pulmonary Tuberculosis, TB
- Medical subject headings
- Tuberculosis, Tuberculosis, Pulmonary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TBA-354Drug
TBA-354 PlaceboDrug
| Study group | Role | What they receive |
|---|---|---|
| Dose Level 1: 50 mg TBA-354 | Experimental | 50 mg TBA-354 for 14 days (two 25 mg once daily) Receives: Drug: TBA-354 |
| Dose Level 1: Placebo | Placebo comparator | Placebo cohort for Dose Level 1 Receives: Drug: TBA-354 Placebo |
| Dose Level 2: 100 mg TBA-354 | Experimental | 100 mg TBA-354 for 14 days (one 100 mg tablet once daily) Receives: Drug: TBA-354 |
| Dose Level 2: Placebo | Placebo comparator | Placebo cohort for Dose Level 2 Receives: Drug: TBA-354 Placebo |
| Dose Level 3: 200 mg TBA-354 | Experimental | 200 mg TBA-354 for 14 days (two 100 mg once daily) Receives: Drug: TBA-354 |
| Dose Level 3: Placebo | Placebo comparator | Placebo cohort for Dose Level 3 Receives: Drug: TBA-354 Placebo |
| Dose Formulation Comparison Cohort | Experimental | All subjects in this cohort will receive two doses of the active drug. The first dose in three subjects will be a 100 mg TBA-354 tablet, followed 14 days later by a 100 mg dose of the TBA-354 suspension formulation. The first dose in the other three subjects will be 100 mgs of the TBA-354 suspension formulation, followed 14 days later by a 100 mg TBA-354 tablet dose. Placebo formulations will not be used in the dose formulation comparison cohort.
Each dose will be administered orally with 200 ml of water after a minimum 8 hour overnight fast. Food will be given two hours after each dose. Receives: Drug: TBA-354 |
What is being measured
The primary outcome is the main question the study is designed to answer.
The comparison of the percentage of subjects per dose cohort with treatment emergent adverse events (TEAEs) from Days 1 to 28 compared to placebo
Measured: Multiple Ascending Dose Cohorts: Days 1-28, Dose Formulation Cohort: Days 1-28
The percent of subjects per cohort with safety electrocardiogram change-from-baseline QTcF intervals of >30 milliseconds and =>60 milliseconds.
QTcF = QT interval correct by Fridericia's method, percent = number of events/number of subjects
Measured: Multiple Ascending Dose Data Time Point Days 1-3, 8, 12, 14-15, 21; Dose Formulation Cohort Data Time Point Days 1-3,7,14-16, 20
Secondary outcomes (3)
The mean Tmax of TBA-354 per dose cohort in plasma following dosing
Acronyms: Tmax = Time of the maximum drug concentration (obtained without interpolation).
Measured: Multiple Ascending Dose Cohort: Days 1-14, Dose Formulation Cohort: Days 1-20
The mean Cmax of TBA-354 per dose cohort in plasma following dosing
Acronyms: Cmax= Maximum observed drug concentration
Measured: Multiple Ascending Dose Cohort: Days 1-14, Dose Formulation Cohort: Days 1-20
The mean AUC0-24 of TBA-354 per dose cohort in plasma following dosing
Acronyms: AUC0-24= Area under concentration time curve 0 to 24 hours
Measured: Multiple Ascending Dose Cohort: Days 1-14, Dose Formulation Cohort: Days 1-20
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Nov 2015 (estimated)
- Study startNov 2015
- Primary completionDec 2015
- Study completionDec 2016
Why it stopped: Clinical Hold from FDA
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for TuberculosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 18 participants (actual)
Sponsor and investigators
- Lead sponsor
- Global Alliance for TB Drug Development
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02606214
- Sponsor's protocol ID
- TBA-354-CL-002
- Status last verified
- Sep 2019
- First submitted
- 5 Nov 2015
- Last updated
- 18 Sep 2019
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I, Double-Blind, Placebo Controlled, Randomized, Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
- ClinicalTrials.gov ID
- NCT02606214
- Acronym / sponsor ID
- TBA-354-CL-002
- Conditions
- Tuberculosis
- Keywords
- Tuberculosis, TBA-354, Pulmonary Tuberculosis, TB
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Clinical Hold from FDA
- Enrolment
- 18 participants (actual)
- Lead sponsor
- Global Alliance for TB Drug DevelopmentUniversity, hospital or other
- Study start
- Nov 2015
- Primary completion
- Dec 2015 (actual)
- Study completion
- Dec 2016 (actual)
- First posted
- 17 Nov 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the study is to evaluate the safety and tolerability of multiple doses of TBA-354 in healthy subjects.
Detailed description
This is a randomized, double-blind, placebo-controlled, multiple ascending dose study conducted at one study center in the United States. Three (3) multiple ascending dose cohorts are planned with twelve (12) healthy subjects (9 active and 3 placebo) in each cohort. There will also be a dose formulation comparison cohort, enrollment of six (6) subjects is planned. An additional multiple dose cohort of twelve (12) subjects may be enrolled.
Safety will be assessed throughout the study; serial ECGs and serial blood samples will be collected for the safety and pharmacokinetics (PK) assessment of TBA-354.
Dose escalation to the next cohort (i.e., dose level) will not take place until the Sponsor, in conjunction with the Principal Investigator, has determined that adequate safety, tolerability and PK from the previous cohort has been demonstrated to permit proceeding to the next cohort. Upon review of cohort data, the Sponsor, in conjunction with the Principal Investigator, may decide to:
- Escalate the dose as planned.
- Evaluate an intermediate dose level prior to proceeding to the next planned dose level if concerns arise from PK and safety that do not warrant in ceasing escalation.
- Repeat a given dose level in a new cohort of subjects.
- Increase the dose of the next cohort if the PK is lower than expected in the previous cohort.
- Add a cohort if the PK is lower than expected after a cohort and there are no safety concerns.
- Halt the study.
During dose escalation, at no time will the projected Cmax of any individual exceed 7.6 µg/mL, which is the highest mean value at the no-observed-adverse-effect-level from the 3-month log toxicology study TBA 354 NCLN-103. The predicted median Cmax of the final cohort can exceed 3.2 µg/mL only if there have been no safety concerns.
Subjects in the Multiple Ascending Dose (MAD) Cohorts will be housed in the Celerion clinic from check-in to Day 15. Subjects will return to the clinic each day from Day 16-Day 21 and have a final one-week follow up phone interview upon completion. Subjects in the Dose Formulation Cohort will be housed in the Clerion clinic from check-in to Day 3, visit the clinic each day for Days 4-7, and be housed in the clinic for Days 14-16. Then subjects will return for a daily visit for Days 17-20, and be contacted for a final one-week follow up phone interview upon completion on Day 28.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 7
| Arm | Type | Receives |
|---|---|---|
| Dose Level 1: 50 mg TBA-354 | Experimental | Drug: TBA-35450 mg TBA-354 for 14 days (two 25 mg once daily) |
| Dose Level 1: Placebo | Placebo comparator | Drug: TBA-354 PlaceboPlacebo cohort for Dose Level 1 |
| Dose Level 2: 100 mg TBA-354 | Experimental | Drug: TBA-354100 mg TBA-354 for 14 days (one 100 mg tablet once daily) |
| Dose Level 2: Placebo | Placebo comparator | Drug: TBA-354 PlaceboPlacebo cohort for Dose Level 2 |
| Dose Level 3: 200 mg TBA-354 | Experimental | Drug: TBA-354200 mg TBA-354 for 14 days (two 100 mg once daily) |
| Dose Level 3: Placebo | Placebo comparator | Drug: TBA-354 PlaceboPlacebo cohort for Dose Level 3 |
| Dose Formulation Comparison Cohort | Experimental | Drug: TBA-354All subjects in this cohort will receive two doses of the active drug. The first dose in three subjects will be a 100 mg TBA-354 tablet, followed 14 days later by a 100 mg dose of the TBA-354 suspension formulation. The first dose in the other three subjects will be 100 mgs of the TBA-354 suspension formulation, followed 14 days later by a 100 mg TBA-354 tablet dose. Placebo formulations will not be used in the dose formulation comparison cohort. Each dose will be administered orally with 200 ml of water after a minimum 8 hour overnight fast. Food will be given two hours after each dose. |
Who may qualify
- Ages
- 19 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (17 listed)
- Healthy adult male and females of non-childbearing potential, 19 to 50 years of age (inclusive) at the time of screening.
- Body mass index (BMI) ≥ 18.5 and ≤ 32.0 (kg/m2) and a body weight of no less than 50.0 kg.
- Medically healthy with no clinically significant screening results (e.g., laboratory profiles, medical histories, vital signs, ECGs, physical examination) as deemed by the Investigator.
- No use of tobacco or nicotine containing products (including smoking cessation products), for a minimum of 6 months prior to dosing.
- Females of non-childbearing potential, having undergone one of the following sterilization procedures at least 6 months prior to dosing:
Key exclusion criteria (38 listed)
- History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease as determined by the Investigator to be clinically relevant.
- History of any illness that, in the opinion of the Investigator, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
- Surgery within the past 90 days prior to dosing as determined by the Investigator to be clinically relevant.
- History or presence of alcoholism or drug abuse within the past 2 years as determined by the Investigator to be clinically relevant.
- Hypersensitive or idiosyncratic reactions to compounds related to TBA-354 (e.g., nitroimidazoles such as metronidazole, etc.).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TBA-354 | Drug | Dose Formulation Comparison Cohort, Dose Level 1: 50 mg TBA-354, Dose Level 2: 100 mg TBA-354, Dose Level 3: 200 mg TBA-354 |
| TBA-354 Placebo | Drug | Dose Level 1: Placebo, Dose Level 2: Placebo, Dose Level 3: Placebo |
Primary outcome
The comparison of the percentage of subjects per dose cohort with treatment emergent adverse events (TEAEs) from Days 1 to 28 compared to placebo
Time frame: Multiple Ascending Dose Cohorts: Days 1-28, Dose Formulation Cohort: Days 1-28
The percent of subjects per cohort with safety electrocardiogram change-from-baseline QTcF intervals of >30 milliseconds and =>60 milliseconds.
Time frame: Multiple Ascending Dose Data Time Point Days 1-3, 8, 12, 14-15, 21; Dose Formulation Cohort Data Time Point Days 1-3,7,14-16, 20
QTcF = QT interval correct by Fridericia's method, percent = number of events/number of subjects
3 secondary outcomes
The mean Tmax of TBA-354 per dose cohort in plasma following dosing
Time frame: Multiple Ascending Dose Cohort: Days 1-14, Dose Formulation Cohort: Days 1-20
The mean Cmax of TBA-354 per dose cohort in plasma following dosing
Time frame: Multiple Ascending Dose Cohort: Days 1-14, Dose Formulation Cohort: Days 1-20
The mean AUC0-24 of TBA-354 per dose cohort in plasma following dosing
Time frame: Multiple Ascending Dose Cohort: Days 1-14, Dose Formulation Cohort: Days 1-20
Results and safety
The study was stopped early (reason given: Clinical Hold from FDA). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2019.
Related trials for Tuberculosis
Enrolling by invitation
Evaluation of New TB Diagnostic Tests (NATs) in Pakistan
Tuberculosis Diagnosis
RecruitingObservational study
Training Protocol on the Natural History of Tuberculosis
Mycobacterium Infections, Tuberculosis, Multidrug-Resistant
Recruiting
Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment
Drug Resistant Tuberculosis
RecruitingPhase 3
Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)
Tuberculosis (TB)
RecruitingPhase 3
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing TBA-354 in people with Tuberculosis, run by Global Alliance for TB Drug Development.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 38 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 18 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Clinical Hold from FDA). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The comparison of the percentage of subjects per dose cohort with treatment emergent adverse events (TEAEs) from Days 1 to 28 compared to placebo (time frame: Multiple Ascending Dose Cohorts: Days 1-28, Dose Formulation Cohort: Days 1-28). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2019; AzTrials last refreshed its copy on 28 Oct 2026.